Chapter 4 116 Time since illness onset, weeks One week Four weeks Twelve weeks Severity group Overall Mild Moderate Severe/ Critical p- value Overall Mild Moderate Severe/ Critical p- value Overall Mild Moderate Severe/ Critical pvalue Confusion 55 (22%) 20 (23%) 26 (23%) 9 (18%) 0.76 68 (28%) 23 (27%) 32 (28%) 13 (27%) 0.96 74 (32%) 23 (28%) 37 (34%) 14 (32%) 0.69 Nausea 52 (21%) 21 (24%) 22 (19%) 9 (18%) 0.60 78 (32%) 26 (31%) 37 (33%) 15 (31%) 0.94 79 (34%) 26 (32%) 38 (35%) 15 (34%) 0.89 Diarrhoea 40 (16%) 8 (9%) 20 (18%) 12 (24%) 0.057 54 (22%) 8 (9%) 27 (24%) 19 (39%) <0.001 57 (24%) 8 (10%) 30 (28%) 19 (44%) <0.001 Wheeze 36 (14%) 14 (16%) 13 (11%) 9 (18%) 0.44 56 (23%) 16 (19%) 24 (21%) 16 (33%) 0.18 58 (25%) 17 (21%) 25 (23%) 16 (37%) 0.25 Skin rash 10 (4%) 5 (6%) 4 (4%) 1 (2%) 0.59 22 (9%) 8 (9%) 11 (9%) 3 (6,%) 0.80 28 (12%) 8 (10%) 17 (15%) 3 (6%) 0.22 Severe and critical groups combined due to low numbers of prospectively-enrolled critical patients (n=11). Groups compared using the Pearson χ2 test (or Fisher exact test if n<5). Illness onset defined as date of diagnosis for asymptomatic participants, who contributed to the denominator of the incidence proportion. No loss to follow-up occurred prior to one week after illness onset. Number of participants lost to follow-up between 1 and 4 weeks after illness onset were: n=3 (mild), n=3 (moderate), n=2 (severe/critical) and between 4 and 12 weeks after illness onset: n=3 (mild), n=4 (moderate) and n=5 (severe/critical).
RkJQdWJsaXNoZXIy MTk4NDMw